183 related articles for article (PubMed ID: 15547525)
21. Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments.
Kyrgiou M; Salanti G; Pavlidis N; Paraskevaidis E; Ioannidis JP
J Natl Cancer Inst; 2006 Nov; 98(22):1655-63. PubMed ID: 17105988
[TBL] [Abstract][Full Text] [Related]
22. Paclitaxel-ifosfamide-cisplatin as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and paclitaxel.
Polyzos A; Kosmas C; Tsavaris N; Toufexi H; Lagadas A; Gogas H; Giannakopoulos K; Kouraklis G; Griniatsos J; Felekouras E; Tsigris C; Nikiteas N; Papadopoulos O; Giannopoulos A
Anticancer Res; 2007; 27(3B):1645-51. PubMed ID: 17595790
[TBL] [Abstract][Full Text] [Related]
23. Epigenetics and ovarian cancer.
Nephew KP; Balch C; Zhang S; Huang TH
Cancer Treat Res; 2009; 149():131-46. PubMed ID: 19763434
[No Abstract] [Full Text] [Related]
24. Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents.
Bishton M; Kenealy M; Johnstone R; Rasheed W; Prince HM
Expert Rev Anticancer Ther; 2007 Oct; 7(10):1439-49. PubMed ID: 17944568
[TBL] [Abstract][Full Text] [Related]
25. Differential modulation of nuclear texture, histone acetylation, and MDR1 gene expression in human drug-sensitive and -resistant OV1 cell lines.
Yatouji S; El-Khoury V; Trentesaux C; Trussardi-Regnier A; Benabid R; Bontems F; Dufer J
Int J Oncol; 2007 Apr; 30(4):1003-9. PubMed ID: 17332941
[TBL] [Abstract][Full Text] [Related]
26. New and emerging intraperitoneal (IP) drugs for ovarian cancer treatment.
Muggia FM
Semin Oncol; 2006 Dec; 33(6 Suppl 12):S18-24. PubMed ID: 17223446
[TBL] [Abstract][Full Text] [Related]
27. Histone deacetylase inhibitors enhance the chemosensitivity of tumor cells with cross-resistance to a wide range of DNA-damaging drugs.
Ozaki K; Kishikawa F; Tanaka M; Sakamoto T; Tanimura S; Kohno M
Cancer Sci; 2008 Feb; 99(2):376-84. PubMed ID: 18201278
[TBL] [Abstract][Full Text] [Related]
28. Epigenome: a new target in cancer therapy.
Giacinti L; Vici P; Lopez M
Clin Ter; 2008; 159(5):347-60. PubMed ID: 18998037
[TBL] [Abstract][Full Text] [Related]
29. The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia.
Dobosy JR; Roberts JL; Fu VX; Jarrard DF
J Urol; 2007 Mar; 177(3):822-31. PubMed ID: 17296351
[TBL] [Abstract][Full Text] [Related]
30. Demethylation of the MCJ gene in stage III/IV epithelial ovarian cancer and response to chemotherapy.
Strathdee G; Vass JK; Oien KA; Siddiqui N; Curto-Garcia J; Brown R
Gynecol Oncol; 2005 Jun; 97(3):898-903. PubMed ID: 15894365
[TBL] [Abstract][Full Text] [Related]
31. Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro.
Yanagie H; Hisa T; Ogata A; Miyazaki A; Nonaka Y; Nishihira T; Osada I; Sairennji T; Sugiyama H; Furuya Y; Kidani Y; Takamoto S; Takahashi H; Eriguchi M
Biomed Pharmacother; 2009 Sep; 63(8):553-60. PubMed ID: 18571892
[TBL] [Abstract][Full Text] [Related]
32. Activity of chemotherapy in mucinous epithelial ovarian cancer: a retrospective study.
Pisano C; Greggi S; Tambaro R; Losito S; Iodice F; Di Maio M; Ferrari E; Falanga M; Formato R; Iaffaioli VR; Pignata S
Anticancer Res; 2005; 25(5):3501-5. PubMed ID: 16101169
[TBL] [Abstract][Full Text] [Related]
33. Epigenetics of ovarian cancer: from the lab to the clinic.
Asadollahi R; Hyde CA; Zhong XY
Gynecol Oncol; 2010 Jul; 118(1):81-7. PubMed ID: 20421130
[TBL] [Abstract][Full Text] [Related]
34. New players in ovarian cancer.
Bovicelli A; D'Andrilli G; Giordano A
J Cell Physiol; 2011 Oct; 226(10):2500-4. PubMed ID: 21302305
[TBL] [Abstract][Full Text] [Related]
35. Tumor suppressor genes associated with drug resistance in ovarian cancer (review).
Yin F; Liu X; Li D; Wang Q; Zhang W; Li L
Oncol Rep; 2013 Jul; 30(1):3-10. PubMed ID: 23660957
[TBL] [Abstract][Full Text] [Related]
36. Genomic and Epigenomic Signatures in Ovarian Cancer Associated with Resensitization to Platinum Drugs.
Fang F; Cardenas H; Huang H; Jiang G; Perkins SM; Zhang C; Keer HN; Liu Y; Nephew KP; Matei D
Cancer Res; 2018 Feb; 78(3):631-644. PubMed ID: 29229600
[TBL] [Abstract][Full Text] [Related]
37. Epigenetic therapy and chemosensitization in solid malignancy.
Ronnekleiv-Kelly SM; Sharma A; Ahuja N
Cancer Treat Rev; 2017 Apr; 55():200-208. PubMed ID: 28431263
[TBL] [Abstract][Full Text] [Related]
38. Epigenetic mechanisms and therapeutic targets of chemotherapy resistance in epithelial ovarian cancer.
Borley J; Brown R
Ann Med; 2015; 47(5):359-69. PubMed ID: 26158617
[TBL] [Abstract][Full Text] [Related]
39. Role of epigenomics in ovarian and endometrial cancers.
Balch C; Matei DE; Huang TH; Nephew KP
Epigenomics; 2010 Jun; 2(3):419-47. PubMed ID: 22121902
[TBL] [Abstract][Full Text] [Related]
40. Epigenetic therapy for ovarian cancer: promise and progress.
Moufarrij S; Dandapani M; Arthofer E; Gomez S; Srivastava A; Lopez-Acevedo M; Villagra A; Chiappinelli KB
Clin Epigenetics; 2019 Jan; 11(1):7. PubMed ID: 30646939
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
